Press Releases May 13, 2026 04:46 PM

Raymond James Financial Declares Quarterly Dividend on Common Stock

Raymond James Financial Announces Quarterly Dividend of $0.54 Per Share

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
RJF

Raymond James Financial, Inc. declared a quarterly cash dividend of $0.54 per share payable on July 15, 2026, reflecting the company's commitment to returning value to shareholders. The firm is a comprehensive financial services provider with $1.76 trillion in client assets and is listed on the NYSE under RJF.

Raymond James Financial Declares Quarterly Dividend on Common Stock
RJF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Declaration of a $0.54 per share quarterly dividend, with payment set for July 15, 2026.
  • Raymond James is a major diversified financial services firm with vast assets under management ($1.76 trillion).
  • The company's dividend reflects stability and confidence in ongoing financial performance, important for investor sentiment.

St. Petersburg, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- On May 13, 2026, the Raymond James Financial, Inc. (NYSE: RJF) Board of Directors declared a quarterly cash dividend on shares of its common stock of $0.54 per share, payable July 15, 2026 to shareholders of record on July 1, 2026.

About Raymond James Financial, Inc.

Raymond James Financial, Inc. (NYSE: RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. Total client assets are $1.76 trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com.

Forward-Looking Statements

Certain statements made in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning future shareholder distributions. Forward-looking statements are not guarantees, and they involve risks, uncertainties and assumptions. Although we make such statements based on assumptions that we believe to be reasonable, there can be no assurance that actual results will not differ materially from those expressed in the forward-looking statements. We caution investors not to rely unduly on any forward-looking statements and urge you to carefully consider the risks described in our filings with the Securities and Exchange Commission (the “SEC”) from time to time, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are available at www.raymondjames.com and the SEC’s website at www.sec.gov. We expressly disclaim any obligation to update any forward-looking statement in the event it later turns out to be inaccurate, whether as a result of new information, future events, or otherwise.


Risks

  • Forward-looking statements about future shareholder distributions come with inherent uncertainties and may not materialize as expected.
  • Economic and market conditions impacting the financial sector could affect company profitability and dividend sustainability.
  • Regulatory changes or adverse financial market movements could negatively influence the firm's business operations and shareholder returns.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026